Details of the Drug

General Information of Drug (ID: DM37CX4)

Drug Name
IC14
Synonyms CD14 antibody
Indication
Disease Entry ICD 11 Status REF
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [1]
Sepsis 1G40-1G41 Phase 2 [2]
Therapeutic Class
Antiviral Agents
Drug Type
Monoclonal antibody
Cross-matching ID
TTD ID
D0JT6Q

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HUAMN monocyte differentiation antigen CD14 (CD14) TTCLGZ8 CD14_HUMAN Inhibitor [1]
Monocyte differentiation antigen CD14 (CD14) TT6I7DC CD14_HUMAN Not Available [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Coronavirus Disease 2019 (COVID-19)
ICD Disease Classification 1D6Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Monocyte differentiation antigen CD14 (CD14) DTT CD14 5.74E-14 1.61 1.11
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 IC14 (Anti-CD14) Treatment in Patients With SARS-CoV-2 (COVID-19)
2 ClinicalTrials.gov (NCT00233207) IC14 Antibodies to Treat Individuals With Acute Lung Injury. U.S. National Institutes of Health.
3 IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis. J Endotoxin Res. 2001;7(4):310-4.